Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Coya Therapeutics

Tracked across 8 events · 150 articles · First seen Feb 11, 2025 · Last active Sep 15, 2026

Sentiment
21
Attention
6
Events
8
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Tech
Impact: Coya Therapeutics is the biopharmaceutical company developing Lonvoguran ziclumeran, a CRISPR-based gene editing therapy for hereditary angioedema. The presentation of Phase 3 HAELO clinical trial data is a significant milestone for the company, potentially leading to a one-time treatment for HAE.
Jun 01, 2026 · 6 articles
4 70
Business
Impact: Coya Therapeutics Inc. is being acquired by ClinActiv Holdings Inc. for $0.80 per share, leading to its delisting from the Toronto Stock Exchange and ceasing to be a reporting issuer.
May 20, 2026 · 7 articles
2 10
Business
Impact: Coya Therapeutics will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026, providing an opportunity to present its pipeline and strategy to investors and potentially increase its visibility and investor interest.
Jun 02, 2026 · 7 articles
2 10
Business
Impact: Coya Therapeutics is a publicly traded company presenting at the conference, seeking to engage with investors and highlight its advancements.
Apr 02, 2026 · 7 articles
6 10
Domestic
Impact: Biotech company that had public disagreements with FDA. Regulatory changes could impact its product approvals.
Aug 19, 2026 · 101 articles
2 0
Business
Impact: Dieter Weinand currently serves on the board of Coya Therapeutics, and will reduce his board seats to focus on his role at Evotec.
Apr 07, 2026 · 9 articles
2 0
Business
Cloverleaf Bio, an RNA therapeutics company spun out of Yale University and headquartered in New Haven, Connecticut, closed an upsized and oversubscribed $33 million seed financing round. The round was led by 4BIO Capital and…
Impact: Mentioned only as the former employer of advisor Michael Mann; no direct role in the event.
Sep 08, 2026 · 6 articles
1 0
Business
Avacta Group Therapeutics, a clinical-stage biopharmaceutical company listed on AIM under ticker AVCT, announced on September 14, 2026 the appointment of seasoned biotechnology finance executive Mats Blom to its Board of Directors as a non-executive…
Impact: Nasdaq-listed company where Mats Blom was previously a board member; mentioned as background.
Sep 14, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Coya Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.